Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09XRQ
|
|||
| Former ID |
DIB004526
|
|||
| Drug Name |
HCBE-11
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Biogen Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lymphotoxin beta receptor (LTBR) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NF-kappa B signaling pathway | ||||
| HIF-1 signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| HTLV-I infection | ||||
| Viral carcinogenesis | ||||
| Reactome | TNFR2 non-canonical NF-kB pathway | |||
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00105170) Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Lymphotoxin beta receptor activation on macrophages induces cross-tolerance to TLR4 and TLR9 ligands. J Immunol. 2012 Apr 1;188(7):3426-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.